Project Three: Assessing effects of anti-CD52g Mabs on STD pathogens in semen

项目3的目标是确定人类避孕抗体(HCA)是否与 中和精液中的性病病原体。这些实验背后的理论基础是我们的观察 男性生殖道限制性抗原CD52g是HCA的靶标。插入通孔 GPI锚定在精液中白细胞和寄生虫的质膜上。我们假设 HCA将结合并中和精液中感染艾滋病毒的细胞，以及被包裹的病毒 从感染了CD52g的男性生殖道细胞中提取CD52g。这些措施的结果 研究将证明HCA是否具有避孕剂和性传播感染的双重活性 杀微生物剂。 我们的具体目标是： 1.确定CD52g是否附着于精液白细胞、性传播感染病毒(HIV-1、HSV-2和 ZIKV)和阴道毛滴虫。 2.确定HCA是否与HIV感染的精液白细胞、性传播感染病毒和 阴道毛滴虫。并抑制它们感染目标细胞的能力。 3.确定包被CD52g的精液白细胞、病毒和寄生虫 经HCA处理后，与彼此或与精子发生凝集。 4.确定HCA及其工程变体是否捕获CD52g包被的白细胞，STI 宫颈粘液中的病毒和寄生虫(与项目2合作)

The goal of Project 3 is to determine whether Human Contraception Antibody (HCA) binds to and neutralizes STI pathogens in semen. The rationale behind these experiments is our observation that the male reproductive tract restricted antigen CD52g, which is the target of HCA. inserts via GPI anchor into the plasma membrane of leukocytes and parasites in semen. We hypothesize that HCA will bind to and neutralize HIV infected cells in semen, as well as enveloped viruses that pick up CD52g from infected CD52g-coated cells in the male genital tract. Results of these studies will demonstrate whether HCA has dual activity as a contraceptive agent and STI microbicide. Our Specific Aims are: 1. Determine whether CD52g attaches to seminal leukocytes, STI viruses (HIV-1, HSV-2 and ZIKV) and Trichomonas vaginalis. 2. Determine whether HCA binds to HIV-infected seminal leukocytes, STI viruses and Trichomonas vaginalis. and inhibits their ability to infect target cells. 3. Determine whether seminal leukocytes, viruses and parasites that are coated with CD52g agglutinate with each other or with sperm after treatment with HCA. 4. Determine whether HCA and engineered variants of HCA trap CD52g-coated leukocytes, STI viruses and parasites in cervical mucus (collaboration with Project 2)